Agents used for treating tissue damage
Small molecule CRP-binding inhibitors form stable complexes with CRP to prevent complement activation, reducing tissue damage and disease severity in conditions like myocardial infarction and stroke.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- UCL BUSINESS LTD
- Filing Date
- 2025-12-22
- Publication Date
- 2026-05-26
AI Technical Summary
C-reactive protein (CRP) exacerbates tissue damage in various disease conditions by binding to damaged cell membranes and activating the complement system, leading to severe tissue damage and worsening disease outcomes.
Development of small molecule CRP-binding inhibitors, such as bis(phosphocholine) compounds, that inhibit CRP binding to ligands, forming stable complexes with CRP molecules to prevent complement activation and tissue damage.
The inhibitors effectively reduce the severity and duration of tissue damage in conditions like myocardial infarction and stroke by blocking CRP's pathogenic effects, offering a therapeutic approach to mitigate CRP-mediated tissue damage across a range of diseases.
Smart Images

Figure 2026086392000001 
Figure 2026086392000002 
Figure 2026086392000003